Lulu Sun

Lulu Sun

Auto-generated profile, based on publicly available information

Lulu Sun

Division of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
ASAshley L. Steed
Ashley L. Steed
GCGeorge P. Christophi
George P. Christophi
GKGerard Kaiko
Gerard Kaiko
LSLulu Sun
Lulu Sun
VGVictoria M. Goodwin
Victoria M. Goodwin
TSThaddeus S. Stappenbeck
Thaddeus S. Stappenbeck
Eat more plants for influenza resilience: Antibiotic treatment worsens influenza in mice, possibly because the concomitant loss of the microbiota interrupts the production of bioactive metabolites. Steed et al. found that a microbial product, desaminotyrosine (DAT), produced by an obligate clostridial anaerobe from the digestion of plant flavonoids, is beneficial during influenza. DAT enters the bloodstream and triggers type I interferon signaling, which then augments antiviral responses by phagocytic cells. Without DAT, influenza virus causes inflammation and severe disease. Science , this issue p. 498

1 May 2011 in Cell Host & Microbe
Verified
Journal Article
Closed access
SBSeth M. Bloom
Seth M. Bloom
VBVinieth N. Bijanki
Vinieth N. Bijanki
GNGerardo Nava
Gerardo Nava
LSLulu Sun
Lulu Sun
NMNicole P. Malvin
Nicole P. Malvin
TSThaddeus S. Stappenbeck
Thaddeus S. Stappenbeck

1 January 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
LSLulu Sun
Lulu Sun
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
SOSofia Origanti
Sofia Origanti
TNTimothy J. Nice
Timothy J. Nice
ABAlexandra C. Barger
Alexandra C. Barger
TSThaddeus S. Stappenbeck
Thaddeus S. Stappenbeck

25 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluorescence in HGSOC patient-derived cell lines (n = 5), organoids (n = 11), and formalin-fixed, paraffin-embedded tumor samples (discovery n = 31, validation n = 148). Samples were defined as RAD51-High if >10% of geminin-positive cells had ≥5 RAD51 foci. Associations between RAD51 scores, platinum chemotherapy response, and survival were evaluated. Results: RAD51 scores correlated with in vitro response to platinum chemotherapy in established and primary ovarian cancer cell lines (Pearson r = 0.96, P = 0.01). Organoids from platinum-nonresponsive tumors had significantly higher RAD51 scores than those from platinum-responsive tumors (P < 0.001). In a discovery cohort, RAD51-Low tumors were more likely to have a pathologic complete response (RR, 5.28; P < 0.001) and to be platinum-sensitive (RR, ∞; P = 0.05). The RAD51 score was predictive of chemotherapy response score [AUC, 0.90; 95% confidence interval (CI), 0.78–1.0; P < 0.001). A novel automatic quantification system accurately reflected the manual assay (92%). In a validation cohort, RAD51-Low tumors were more likely to be platinum-sensitive (RR, ∞; P < 0.001) than RAD51-High tumors. Moreover, RAD51-Low status predicted platinum sensitivity with 100% positive predictive value and was associated with better progression-free (HR, 0.53; 95% CI, 0.33–0.85; P < 0.001) and overall survival (HR, 0.43; 95% CI, 0.25–0.75; P = 0.003) than RAD51-High status. Conclusions: RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.

1 July 2011 in Current Opinion in Gastroenterology
Verified
Journal Article
Closed access
LSLulu Sun
Lulu Sun
GNGerardo Nava
Gerardo Nava
TSThaddeus S Stappenbeck
Thaddeus S Stappenbeck
Purpose of review Inflammatory bowel disease (IBD) is thought to occur in genetically susceptible individuals. However, environmental factors, potentially including shifts in commensal microbiota, are also required to trigger disease. This review discusses some of the recent discoveries in host susceptibility and interaction with the microbial environment, and pinpoints key areas for advancement in our understanding of IBD pathogenesis. Recent findings Meta-analyses of genome-wide association studies have uncovered many new exciting genes associated with susceptibility loci for IBD. In addition, improved methods to analyze the commensal microbiota pave the way to better define dysbiosis and its potential role in disease. Lastly, identification of viral triggers in experimental systems suggests a potential role for viral infection in IBD. Summary Understanding the precise microbial and immune triggers of IBD in a genetic context will hopefully lead to a better understanding of the pathogenesis of this disease and the discovery of novel therapeutic approaches, including vaccination against specific viruses.

1 August 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LCLiyun Chen
Liyun Chen
VSVictoria Shi
Victoria Shi
SWSongyan Wang
Songyan Wang
LSLulu Sun
Lulu Sun
RFRebecca Freeman
Rebecca Freeman
SMStephanie Markovina
Stephanie Markovina
Patients with cancer who have high serum levels of squamous cell carcinoma antigen 1 (SCCA1, now referred to as SERPINB3) commonly experience treatment resistance and have a poor prognosis. Despite being a clinical biomarker, the modulation of SERPINB3 in tumor immunity is poorly understood. We found positive correlations of SERPINB3 with CXCL1, CXCL8 (CXCL8/9), S100A8, and S100A9 (S100A8/A9) myeloid cell infiltration through RNA-Seq analysis of human primary cervical tumors. Induction of SERPINB3 resulted in increased CXCL1/8 and S100A8/A9 expression, which promoted monocyte and myeloid-derived suppressor cell (MDSC) migration in vitro. In mouse models, Serpinb3a tumors showed increased MDSC and tumor-associated macrophage (TAM) infiltration, contributing to T cell inhibition, and this was further augmented upon radiation. Intratumoral knockdown (KD) of Serpinb3a resulted in tumor growth inhibition and reduced CXCL1 and S100A8/A expression and MDSC and M2 macrophage infiltration. These changes led to enhanced cytotoxic T cell function and sensitized tumors to radiotherapy (RT). We further revealed that SERPINB3 promoted STAT-dependent expression of chemokines, whereby inhibition of STAT activation by ruxolitinib or siRNA abrogated CXCL1/8 and S100A8/ A9 expression in SERPINB3 cells. Patients with elevated pretreatment SCCA levels and high phosphorylated STAT3 (p-STAT3) had increased intratumoral CD11b+ myeloid cells compared with patients with low SCCA levels and p-STAT3, who had improved overall survival after RT. These findings provide a preclinical rationale for targeting SERPINB3 in tumors to counteract immunosuppression and improve the response to RT.